StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) shareholders

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
19.2%
0M of 1M shares
Institutional holders
11
4 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $44.01K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Cortice Biosciences, Inc.573,3685.70%13D (active)Jul 29, 2024
Steven Boyd
Joint filing with Armistice Capital, LLC (9.99%)
561,1489.99%13G (passive)Jun 30, 2025
Jon M. Plexico
Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine Capital, L.P. (9.90%) and 1 more
159,7909.90%13G (passive) amendmentMar 31, 2026
Neil Shahrestani
Joint filing with Ikarian Capital, LLC (9.90%)
147,2909.90%13G (passive) amendmentJun 30, 2026
Stonepine Capital Management, LLC
Joint filing with Stonepine Capital, L.P. (7.90%), Stonepine GP, LLC (7.90%) and 1 more
48,8277.90%13G (passive) amendmentDec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CNSPValueChange% of portfolio
Ikarian Capital, LLC135,8309.29%$649.27K+90,0000.07%
ADAR1 Capital Management, LLC70,0004.79%$334.60KNew0.02%
Stonepine Capital Management, LLC41,5732.84%$198.72K−19,4270.11%
Boothbay Fund Management, LLC13,5240.93%$64.65K–0.00%
Vanguard Fiduciary Trust Co10,2260.70%$48.88KNew0.00%
Vanguard Capital Management LLC6,9930.48%$33.43KNew0.00%
UBS Group AG1,4610.10%$6.98K+7320.00%
Tower Research Capital LLC (TRC)7990.05%$3.82K−5110.00%
Barclays PLC190.00%$91New0.00%
Barrett & Company, Inc.80.00%$38–0.00%
Danske Bank A/S10.00%$5–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026110M19.2%4 / 22 / 40M0M
Q1 2026110M10.0%4 / 20 / 20M0M
Q4 202590M8.5%3 / 11 / 20M0M
Q3 202580M1.7%8 / 00 / 10M0M
Q2 202510M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held CNSP in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CNSPValue% of fundAs of
Vanguard Extended Market Index Fund6,9930.48%$33.43K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund6,7360.46%$36.64K0.00%May 31, 2026
Fidelity Series Total Market Index Fund5550.04%$3.02K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-49-0.00%-$234-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
John M. ClimacoChief Executive Officer, Director215,67614.76%Nov 19, 2025
Rami LevinCEO and President4,7500.33%Aug 18, 2026
Eric FaulknerChief Technology Officer––Mar 4, 2026
Steve O'LoughlinChief Financial Officer––Mar 4, 2026
Christopher DownsChief Financial Officer103,4387.08%Nov 19, 2025
Michal FisherDirector2,0000.14%Aug 18, 2026
Faith L. CharlesDirector7,1000.49%May 20, 2026
Jeffry R. KeyesDirector11,1000.76%Nov 19, 2025
Bettina M. CockroftDirector––Nov 19, 2025
Amy MaheryDirector––Nov 19, 2025
Jerzy GumulkaDirector43,0062.94%Nov 19, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Rami Levin
CEO and President
Aug 14, 2026Option exercise−4,750––4,750
Michal Fisher
Director
May 18, 2026Buy+2,000$5.00$10.00K2,000
Faith L. Charles
Director
May 18, 2026Buy+7,100$4.79$34.01K7,100
Carl Anthony Evans
Director
Feb 1, 2024Buy+33,333$0.30$10.00K33,458
Christopher Downs
Chief Financial Officer
Feb 1, 2024Buy+66,666$0.30$20.00K103,438
Jerzy Gumulka
Director
Feb 1, 2024Buy+33,333$0.30$10.00K43,006
John M. Climaco
Chief Executive Officer, Director
Feb 1, 2024Buy+166,666$0.30$50.00K215,676
Christopher Downs
Chief Financial Officer
Aug 22, 2023Buy+27,000$1.27$34.29K36,772
John M. Climaco
Chief Executive Officer, Director
Aug 16, 2023Buy+2,750$1.80$4.95K49,010
Christopher Downs
Chief Financial Officer
Apr 28, 2023Option exercise+521––9,772
John M. Climaco
Chief Executive Officer, Director
Apr 28, 2023Option exercise+1,250––46,260
Jerzy Gumulka
Director
Apr 19, 2023Buy+2,500$1.70$4.25K9,673
Christopher Downs
Chief Financial Officer
Apr 17, 2023Buy+3,100$3.20$9.92K9,251
John M. Climaco
Chief Executive Officer, Director
Apr 12, 2023Buy+15,000$0.69$10.35K45,010
Jerzy Gumulka
Director
Apr 10, 2023Buy+7,173$0.74$5.31K7,173
Waldemar Priebe
10% owner
Mar 28, 2023Sale(10b5-1 plan)−10,000$1.04$10.40K156,807
Waldemar Priebe
10% owner
Mar 27, 2023Sale(10b5-1 plan)−5,000$1.09$5.45K166,807
Waldemar Priebe
10% owner
Mar 24, 2023Sale(10b5-1 plan)−5,000$1.08$5.40K171,807
Waldemar Priebe
10% owner
Mar 23, 2023Sale(10b5-1 plan)−10,000$1.08$10.80K176,807
Waldemar Priebe
10% owner
Mar 22, 2023Sale(10b5-1 plan)−5,000$1.08$5.40K186,807
Waldemar Priebe
10% owner
Mar 21, 2023Sale(10b5-1 plan)−5,000$1.10$5.50K191,807
Waldemar Priebe
10% owner
Mar 20, 2023Sale(10b5-1 plan)−5,000$1.08$5.40K196,807
Waldemar Priebe
10% owner
Mar 17, 2023Sale(10b5-1 plan)−5,000$1.13$5.65K201,807
Waldemar Priebe
10% owner
Mar 16, 2023Sale(10b5-1 plan)−5,000$1.24$6.20K206,807
Waldemar Priebe
10% owner
Mar 15, 2023Sale(10b5-1 plan)−5,000$1.22$6.10K211,807
Waldemar Priebe
10% owner
Mar 14, 2023Sale(10b5-1 plan)−5,000$1.35$6.75K216,807
Waldemar Priebe
10% owner
Mar 13, 2023Sale(10b5-1 plan)−5,000$1.30$6.50K221,807
Waldemar Priebe
10% owner
Mar 10, 2023Sale(10b5-1 plan)−5,000$1.29$6.45K226,807
Waldemar Priebe
10% owner
Dec 9, 2022Sale(10b5-1 plan)−2,798$2.43$6.80K231,807
Waldemar Priebe
10% owner
Dec 8, 2022Sale(10b5-1 plan)−5,500$2.40$13.20K234,605
Waldemar Priebe
10% owner
Dec 7, 2022Sale(10b5-1 plan)−5,500$2.46$13.53K240,105
Waldemar Priebe
10% owner
Dec 6, 2022Sale(10b5-1 plan)−5,500$2.47$13.59K245,605
Christopher Downs
Chief Financial Officer
Mar 11, 2022Award+33,000$0.31$10.23K184,500
Carl Anthony Evans
Director
Mar 8, 2022Award+3,750$0.27$1.01K3,750
Jeffry R. Keyes
Director
Mar 7, 2022Award+11,100$0.30$3.33K11,100
John M. Climaco
Chief Executive Officer, Director
Mar 7, 2022Award+35,000$0.28$9.80K940,298
Christopher Downs
Chief Financial Officer
Dec 6, 2021Buy+5,000$0.94$4.70K151,500
Christopher Downs
Chief Financial Officer
Nov 19, 2021Buy+4,500$1.15$5.18K146,500
John M. Climaco
Chief Executive Officer, Director
Nov 16, 2021Award+5,000$1.28$6.40K905,298
Christopher Downs
Chief Financial Officer
Aug 24, 2020Buy+142,000$2.04$289.68K142,000
Waldemar Priebe
10% owner
May 5, 2020Other−1,495,867––7,533,133

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.15%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+26.0%
From 0M shares
Short volume, 20 days
33.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CNS Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,534 shares on Sep 8, 2026 over the last 90 days.

See a number that looks wrong?